ASPER Biotech markets genetic test for statin ADR

PREDICTION-ADR partner Asper Biotech is working on the implementation of new reliable and validated testing panels to predict the side effects of statins and ACE inhibitors. Asper’s new testing portfolio – Asper Cardiogenetics – launched in 2015 – offers among other options risk assessment for developing adverse drug reactions, namely statin-induced myopathy. Currently the validated test includes targeted mutation analysis of the SLCO1B1 gene. In addition to the prediction of drug side effects, the test is beneficial for optimizing the statin dose. The initial test has been implemented within the PREDICTION-ADR project.

http://www.asperbio.com/asper-cardiogenetics

Leave a comment

Your email address will not be published.